Double-blind trial of yohimbine in treatment of psychogenic impotence.

Abstract

48 subjects meeting strict diagnostic criteria for psychogenic impotence took part in a 10 week placebo-controlled, double-blind, partial crossover trial of yohimbine (18 mg a day) for restoring erectile function. At the end of the first arm of the trial 62% of the yohimbine group and 16% of the placebo group reported some improvement in sexual function (chi 2 = 10.41, df = 2, p less than 0.05). 21% of the originally placebo-treated group noticed some improvement over pre-treatment levels when they were put on yohimbine in the second arm of the trial. Overall 46% of those who received yohimbine reported a positive response to the drug, a response rate very similar to that observed in a previous study of patients with organic impotence. Response to yohimbine thus seems to be unrelated to current groupings of the cause of impotence. Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning.

• Authors: K Reid, D H Surridge, A Morales, M Condra, C Harris, J Owen, J Fenemore
• Journal: Lancet (London, England) (Lancet) Vol. 2 Issue 8556 Pg. 421-3 (Aug 22 1987) ISSN: 0140-6736 [Print] England
• PMID: 2887726 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Yohimbine

Topics

• Adolescent
• Adult
• Aged
• Clinical Trials as Topic
• Double-Blind Method
• Erectile Dysfunction (diagnosis, drug therapy, psychology)
• Humans
• Male
• Middle Aged
• Random Allocation
• Yohimbine (therapeutic use)